Patented Medicine Prices Review Board Issues a Notice of Hearing for Allegations of Excessive Pricing of Soliris
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwired) -- 01/22/15 -- Patented Medicine Prices Review Board
The Patented Medicine Prices Review Board will hold a public hearing in the matter of the price of the patented medicine Soliris, and Alexion Pharmaceuticals Inc. (Alexion), the pharmaceutical company that holds the patent for Soliris and sells the medicine in Canada. Further details on the public hearing and a case management conference will be announced at a later date.
The purpose of the hearing is to determine whether, under section 83 of the Patent Act, Alexion
Soliris is the first and only treatment for patients with Paroxysmal Nocturnal Hemoglobinuria- a rare and life-threatening blood disorder characterized by excessive destruction of red blood cells- and Atypical Hemolytic Uremic Syndrome, a rare and life-threatening genetic disorder characterized by blood clots in small vessels.
Those wishing to participate in this proceeding must apply to the Board for leave to intervene. For further information on the application process, please contact:
Quick Facts
Related Products
-
-
Additional Links
- (Patented Medicine Prices Review Board)
Contacts:
Sofie McCoy-Astell
Manager, Communications
Patented Medicine Prices Review Board
613-960-9728
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.01.2015 - 16:30 Uhr
Sprache: Deutsch
News-ID 366338
Anzahl Zeichen: 0
contact information:
Town:
OTTAWA, ONTARIO
Kategorie:
Local
Diese Pressemitteilung wurde bisher 222 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Patented Medicine Prices Review Board Issues a Notice of Hearing for Allegations of Excessive Pricing of Soliris"
steht unter der journalistisch-redaktionellen Verantwortung von
Patented Medicine Prices Review Board (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
